Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.

Drugs of today (Barcelona, Spain : 1998) - 1 Mar 2013

Haddley K

Abstract excerpt

Alipogene tiparvovec is the first adeno-associated virus (AAV)-mediated gene therapy to be approved for the treatment of a metabolic disorder. Lipoprotein lipase (LPL) deficiency (LPLD) is a rare autosomal-recessive disorder in which gene mutations cause the production of a catalytically inactive enzyme required for plasma triglyceride hydrolysis. The resultant hypertriglyceridemia causes frequent abdominal pain,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Models, Animal
Share to Genetic Therapy
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dependovirus

Share to Genetic Vectors

Share to Hyperlipoproteinemia Type I

Share to Lipoprotein Lipase

Share to Triglycerides

Source

Identifiers

PMID: 23527320
DOI: 10.1358/dot.2013.49.3.1937398

Genes

LPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.PMID 23527320Read ↗

Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice ConditionsSemantic proximity Read ↗

Gene therapy for lipoprotein lipase deficiencySemantic proximity Read ↗

Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPLS447X, Reveals Increased Lipoprotein Uptake.Semantic proximity Read ↗

Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice.Semantic proximity Read ↗

Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera<sup>®</sup>)Semantic proximity Read ↗

A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in miceSemantic proximity Read ↗

Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.Semantic proximity Read ↗

Selective Targeting of Angiopoietin-like 3 (ANGPTL3) with Vupanorsen for the Treatment of Patients with Familial Partial Lipodystrophy (FPLD): Results of a Proof-of-Concept StudySemantic proximity Read ↗

Complete Rescue of Lipoprotein Lipase–Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPLS447XBeneficial MutationSemantic proximity Read ↗

Novel Therapeutics for Familial Chylomicronemia SyndromeSemantic proximity Read ↗

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial.Semantic proximity Read ↗

A lipase fusion feasts on fat.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.